Nuwellis, Inc.

Nuwellis, Inc. Annual Report Summary (Fiscal Year Ended December 31, 2025)

Nuwellis, Inc. (NASDAQ: NUWE) has released its annual 10-K report for the fiscal year ended December 31, 2025. This summary cuts through the technical details to provide retail investors with a clear, concise overview of the company's financial health, operational performance, key risks, and future outlook.

---

Company Overview: Focused on Cardiorenal Care

Nuwellis, Inc. (NASDAQ: NUWE) develops medical devices that improve outcomes for patients suffering from fluid overload, especially those with heart and kidney issues (cardiorenal care).

Their flagship product, the Aquadex System (including FlexFlow® and SmartFlow® versions), performs ultrafiltration therapy. This precise method removes excess fluid from patients who are "fluid overloaded" and do not respond to conventional treatments like diuretics. The Aquadex System is approved for both temporary and longer-term use in adult and pediatric patients weighing 20 kg or more.

The market presents a significant need: over one million U.S. hospitalizations annually stem from fluid overload in heart failure patients, with each costing approximately $24,000. Nuwellis aims to address this critical clinical challenge.

Financial Performance: Persistent Losses and Urgent Capital Needs

For the fiscal year ended December 31, 2025, Nuwellis reported total revenue of $7.8 million, a slight decrease from $8.2 million in the prior year. Slower-than-anticipated market adoption of the Aquadex System primarily drove this decline. The company continues to incur significant operating losses, reporting a net loss of $22.5 million for 2025, compared to $20.1 million in 2024.

As of December 31, 2025, Nuwellis held cash and cash equivalents of $3.5 million. This limited cash position is critical, as the company explicitly stated in its 10-K that it needs additional capital to fund operations beyond the second quarter of 2026. Without this funding, the company's ability to continue operating – its "going concern" – faces substantial doubt.

Risk Factors: A "Going Concern" Warning and Operational Challenges

The most significant challenge Nuwellis faces is the "going concern" warning from management. This indicates substantial doubt about the company's ability to continue operations for the next 12 months without securing additional financing, reflecting a severe liquidity crisis.

Other critical risks and challenges include:

• Single Product Dependence: Nuwellis relies heavily on sales of its Aquadex System. Any issues with product adoption, competition, or regulatory changes could severely impact the company.
• Limited Commercial Experience: The company acknowledges its limited sales and marketing experience, which hinders its ability to effectively expand market reach and drive Aquadex sales.
• Material Weaknesses in Internal Controls: Auditors identified two significant weaknesses in financial reporting controls, pointing to deficiencies in accounting processes. While management works to fix these, they pose risks to financial accuracy and investor confidence.
• Customer Concentration: A few customers generate a significant portion of revenue, making the company vulnerable if it loses any single client.
• Supply Chain Vulnerabilities: Reliance on third-party manufacturers and single-source suppliers for critical components exposes Nuwellis to potential production delays, quality issues, or increased costs.
• Nasdaq Delisting Risk: With a low market capitalization (approximately $4.6 million as of June 30, 2025) and persistent losses, the company risks non-compliance with Nasdaq listing requirements. This could lead to delisting and reduced stock liquidity.
• Dilution Risk: To raise necessary capital, Nuwellis will likely issue new shares. This would dilute existing shareholders' ownership percentage and potentially reduce their share value.
• Intense Competition: Nuwellis operates in a competitive medical device market against larger, more established companies with greater financial and R&D resources.

Management Discussion and Analysis (MD&A) Highlights

Management's discussion emphasizes the critical need for additional capital to sustain operations beyond Q2 2026, underscoring the "going concern" risk. Slower-than-anticipated market adoption, despite the significant market opportunity, caused the revenue decrease. The company acknowledges persistent operating losses as it invests in commercialization. Management is actively remediating identified material weaknesses in internal controls over financial reporting, viewing this as crucial for improving financial accuracy and investor confidence. The MD&A highlights the challenges of commercializing a novel medical device in a competitive environment while managing significant liquidity constraints.

Future Outlook and Strategy

Nuwellis's strategy focuses on expanding market adoption of its Aquadex System. This involves increasing physician and hospital awareness, demonstrating clinical benefits, and navigating reimbursement pathways. The company identifies a large addressable market for fluid overload treatment.

However, the immediate future outlook hinges heavily on the company's ability to successfully raise additional capital by Q2 2026. Without this funding, operational capacity and growth initiatives will face severe constraints. Management anticipates continued operating losses in the near term as they invest in commercialization efforts.

Competitive Position

Nuwellis operates in the highly competitive medical device market for fluid management and cardiorenal care. Key competitors include larger, well-established medical device companies with significantly greater financial, marketing, sales, and research and development resources. These competitors often have broader product portfolios, established distribution channels, and stronger brand recognition.

Nuwellis's competitive strategy highlights the unique benefits and precision of its Aquadex System for ultrafiltration therapy. It aims to differentiate the system from conventional fluid removal methods (like diuretics) and other dialysis or ultrafiltration devices. The company emphasizes clinical outcomes and the system's ease of use and safety profile to gain market share. However, succeeding against entrenched players in this competitive landscape requires continuous innovation and effective market penetration strategies.

Leadership and Regulatory Environment

Dr. Maria Rosa Costanzo resigned from the Board of Directors in January 2026. The company stated this was not due to any disagreement with operations or practices.

As a medical device company, Nuwellis must comply with stringent FDA regulations and broader healthcare reforms. Changes in regulatory approval processes, reimbursement policies, or international trade regulations could significantly impact its business model and market access.

---

Investor Takeaway: Nuwellis, Inc. addresses a significant medical need with its Aquadex System but faces severe financial headwinds, including persistent losses and an urgent need for capital. The "going concern" warning and reliance on a single product are critical considerations for any potential investor. While the market opportunity is real, the company's ability to execute its strategy and secure funding will be paramount to its survival and future growth.